Dr. Shaywitz is currently Chief Medical Officer-in-Residence at BridgeBio, Inc. Prior to this he worked for five years at BioMarin Pharmaceutical where he played key roles in the development of a number of rare disease programs including but not limited to those targeting lysosomal storage diseases and MPS disorders.  He designed and led the early stage clinical studies for the BMN 250 program in Sanfilippo Syndrome Type B and also worked closely with the research and business development teams on portfolio prioritization and in-licensing activities.  Before joining BioMarin Dr. Shaywitz spent four years at Amgen in their early clinical development group focused on advancing promising diabetes and metabolism agents into the clinic.  He received his MD and PhD degrees from Harvard Medical School and trained in adult medicine at Massachusetts General Hospital, in Boston.  He went on to pursue a clinical fellowship in endocrinology, diabetes and metabolism jointly at the Israel-Deaconess Medical Center and Joslin Diabetes Center, both in Boston, where he concurrently pursued postdoctoral studies in molecular physiology.